Literature DB >> 9928473

The role of the FHIT/FRA3B locus in cancer.

K Huebner1, P N Garrison, L D Barnes, C M Croce.   

Abstract

Common fragile sites form gaps at characteristic chromosome bands in metaphases from normal cells after aphidicolin induction. The distribution of common fragile sites parallels the positions of neoplasia-associated chromosomal rearrangements, prompting the proposal that fragility disposes to chromosomal rearrangements. Implicit in this hypothesis is that genes at fragile sites are altered by chromosome rearrangement and thus contribute to neoplastic growth. Chromosome band 3p14.2, encompassing the most inducible common fragile region, FRA3B, has been cloned and the FHIT gene, straddling FRA3B, characterized. The gene is inactivated by deletions in cancer-derived cell lines and primary tumors and Fhit protein is absent or reduced in lung, stomach, kidney, and cervical carcinomas, consistent with function as a tumor suppressor. FRA3B thus fulfills the prophecy that fragile site alterations contribute to the neoplastic process through inactivation of a tumor suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9928473     DOI: 10.1146/annurev.genet.32.1.7

Source DB:  PubMed          Journal:  Annu Rev Genet        ISSN: 0066-4197            Impact factor:   16.830


  45 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  Matrix attachment region (MAR) properties and abnormal expansion of AT island minisatellites in FRA16B fragile sites in leukemic CEM cells.

Authors:  Jennifer A Jackson; Alex V Trevino; Maryanne C Herzig; Terence S Herman; Jan M Woynarowski
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

3.  Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases.

Authors:  Charles Brenner
Journal:  Biochemistry       Date:  2002-07-23       Impact factor: 3.162

4.  Deletion at fragile sites is a common and early event in Barrett's esophagus.

Authors:  Lisa A Lai; Rumen Kostadinov; Michael T Barrett; Daniel A Peiffer; Dimitry Pokholok; Robert Odze; Carissa A Sanchez; Carlo C Maley; Brian J Reid; Kevin L Gunderson; Peter S Rabinovitch
Journal:  Mol Cancer Res       Date:  2010-07-20       Impact factor: 5.852

Review 5.  Hits, Fhits and Nits: beyond enzymatic function.

Authors:  Kay Huebner; Joshua C Saldivar; Jin Sun; Hidetaka Shibata; Teresa Druck
Journal:  Adv Enzyme Regul       Date:  2010-10-28

Review 6.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

7.  Adenosine monophosphoramidase activity of Hint and Hnt1 supports function of Kin28, Ccl1, and Tfb3.

Authors:  Pawel Bieganowski; Preston N Garrison; Santosh C Hodawadekar; Gerard Faye; Larry D Barnes; Charles Brenner
Journal:  J Biol Chem       Date:  2002-01-22       Impact factor: 5.157

8.  FHIT gene therapy prevents tumor development in Fhit-deficient mice.

Authors:  K R Dumon; H Ishii; L Y Fong; N Zanesi; V Fidanza; R Mancini; A Vecchione; R Baffa; F Trapasso; M J During; K Huebner; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

9.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

10.  Reduced Fhit protein expression in nickel-transformed mouse cells and in nickel-induced murine sarcomas.

Authors:  Renata Kowara; Konstantin Salnikow; Bhalchandra A Diwan; Robert M Bare; Michael P Waalkes; Kazimierz S Kasprzak
Journal:  Mol Cell Biochem       Date:  2004-01       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.